Introduction
Recently, the Krebs cycle metabolite succinate was shown to accumulate in macrophages during inflammation, acting as a signal to activate pro-inflammatory gene expression (Tannahill et al., 2013) . Succinate was also found to increase in tissues during ischemia (Chouchani et al., 2014) and during reperfusionpromoted production of reactive oxygen species (ROS) by the mitochondrial respiratory chain, initiating the damage that underlies ischemia-reperfusion (IR) injury (Chouchani et al., 2014 (Chouchani et al., , 2016 . Subsequently, these two strands of work came together: during inflammatory macrophage activation succinate enhanced mitochondrial ROS production using the same process that led to IR injury, with the ROS acting as a pro-inflammatory redox signal to the transcription factor HIF1a. Succinate oxidation by succinate dehydrogenase (SDH) induced production of pro-inflammatory factors, notably IL-1b, and also suppressed production of anti-inflammatory factors (Mills et al., 2016) . A pro-inflammatory signal needs to be switched off, and the next discovery was that the inflammatory effects of succinate were counteracted by the metabolite itaconate (Lampropoulou et al., 2016) . This metabolite is derived from the Krebs cycle intermediate cis-aconitate (Bambouskova et al., 2018; Michelucci et al., 2013; Mills et al., 2018b) . Itaconate was therefore identified as an anti-inflammatory signal. Later, itaconate was shown to upregulate cellular antioxidant defenses via induction of Nrf2 (Bambouskova et al., 2018; Mills et al., 2018b) . We therefore had an intriguing series of observations in which one Krebs cycle intermediate, succinate, acts as a pro-inflammatory signal, which is countered by itaconate, derived from another Krebs cycle intermediate, cis-aconitate.
Succinate is also released from cells and activates a receptor termed SUNCR1 to activate inflammatory pathways (Littlewood-Evans et al., 2016) . Succinate has also been proposed to activate type 2 immunity in the gut to certain infectious agents acting via so-called Tuft cells, which express high levels of SUCRN1 (Lei et al., 2018) . In a model of multiple sclerosis (MS), succinate acted as a pro-inflammatory mediator in the central nervous system upon its release from cells (PeruzzottiJametti et al., 2018) . Succinate-dependent mitochondrial metabolism was also central to how the carotid body senses oxygen and allows the organism to respond to hypoxia (Ferná ndezAgü era et al., 2015) .
Succinate and itaconate have therefore emerged in several areas of cell function, playing key, but opposing, signaling roles that link mitochondrial function to the rest of the cell. Here, we discuss these recent studies and present novel therapeutic options for the injury that occurs in IR and in inflammatory diseases.
Succinate as a Signaling Molecule
Succinate occupies a pivotal position in metabolism as the only direct link between the Krebs cycle and the mitochondrial respiratory chain (Figure 1 ). The other link is provided by NADH, produced by oxidation reactions in the mitochondrial matrix, which also provides electrons for the respiratory chain. SDH links the succinate/fumarate couple to the CoenzymeQ (CoQ) pool, as succinate oxidation to fumarate by SDH is coupled to the reduction of ubiquinone (UQ) to ubiquinol (UQH 2 ) ( Figure 1 ). As the mid-point potentials for the UQ/UQH 2 and the fumarate/succinate couples are close, it enables electrons to flow in either direction across SDH between the Krebs cycle and the CoQ pool, depending on conditions. The close links between the fumarate/succinate ratio and the redox state of the CoQ pool level enables the status of this key determinant of mitochondrial function to be transmitted to the rest of the cell. As succinate is generated in the mitochondrial matrix, its export from the organelle to the cytosol will act as a signal of mitochondrial status. The dicarboxylate carrier SLC25A10 facilitates this by catalyzing the rapid exchange of dianions across the inner membrane with succinate, malate, and phosphate as favored substrates, enabling the mitochondrial succinate pool to equilibrate rapidly with that in the cytosol (Figure 1 ). Of all the mitochondrial respiratory substrates, succinate is the one most frequently supplied when investigating isolated mammalian mitochondria because it is rapidly taken up by the organelle and oxidized by the respiratory chain. But this well-known fact has always been a puzzle: why should mitochondria rapidly take up and oxidize a respiratory substrate that is both generated and consumed within the matrix? We now know why: the main role of the transporter that takes up succinate is actually to export it to the rest of the cell for succinate to act as a signal.
Succinate signaling in the cytosol involves the inhibition of 2-oxoglutarate (2OG)-dependent dioxygenases (Loenarz and Schofield, 2011) . These enzymes generate succinate as a product (Loenarz and Schofield, 2011) . Thus, high levels of succinate slow dioxygenase activity by product inhibition (Figure 1 ). Among these enzymes are prolyl hydroxylases (PHDs), which regulate hypoxia inducible factor 1 (Hif1a). During hypoxia, the lack of O 2 prevents Hif1a degradation and enhances the expression of anti-hypoxia genes (Figure 1 ). High levels of succinate in the cytosol also promote expression of Hif1a-dependent genes, even in the presence of O 2 . There are a number of other 2OG-dependent dioxygenases such as ten eleven translocation (TET) DNA demethylases, which hydroxylate methylcytosines in DNA to erase this epigenetic mark, and the histone lysine demethylase Jumonji C domain-containing proteins, which remove methyl-lysine marks on histones. Hence, elevating cytosolic succinate levels is likely to alter epigenetic marks, with long-term consequences for gene expression. Succinate is generated within mitochondria from 2-oxoglutarate and by reversal of SDH during hypoxia/ischemia. The succinate is then released into the cytosol, where it can act as a signal that stabilizes HIF1a. Succinate can also generate a redox signal by driving mitochondrial ROS production at complex I by reverse electron transport (RET), which also promotes HIF1a. Later in inflammation, the expression of the IRG1/CAD protein in mitochondria can lead to the generation of itaconate from cis-aconitate. This inhibits SDH to limit ROS production in response to succinate. Itaconate is also released into the cytosol, where it modifies KEAP1, leading to Nrf2 activation promoting expression of anti-inflammatory and antioxidant genes. Itaconate also induces ATF3, an anti-inflammatory transcription factor whose activity in part depends on inhibition of IkBz. Succinate-driven ROS can also promote adipose tissue thermogenesis and via SUCNR1 inflammation and type 2 immunity against infectious agents.
Another mode of signaling driven by elevated succinate is ROS production. When the mitochondrial respiratory chain is oxidizing high levels of succinate under conditions of high protonmotive force (Dp)-for example, when mitochondria are not making much ATP-the CoQ pool becomes reduced, leading to reversal of the normal direction of electron flow through complex I, causing reverse electron transport (RET) at complex I (Figure 1) . As RET leads to the dramatic production of ROS, RET enables mitochondria to release a variable redox signal that can respond sensitively to mitochondrial status. This may involve the efflux of ROS such as hydrogen peroxide or more likely by dithiol/sulphide switches on redox-sensitive proteins. ROS will also activate HIF1a and may be the dominant mechanism whereby succinate activates HIF1a in inflammatory macrophages (Mills et al., 2016) .
Succinate is also released from the cell by poorly understood processes (most likely cell death) where it activates the cell surface G-protein-coupled receptor, SUCNR1 (Peruzzotti-Jametti et al., 2018) (see below).
Succinate Accumulation during Ischemia and Anoxia
It had long been known that succinate accumulated to some extent during ischemia and anoxia in vivo, as a consequence of respiratory chain inhibition due to lack of O 2 (Chouchani et al., 2016; Hochachka and Storey, 1975) . Mitchondrial metabolism responds to ischemia (primarily hypoxia) to selectively accumulate succinate as a consequence of the build-up of electrons in the NADH and CoQ pools, in conjunction with the associated breakdown of adenine nucleotides (Chouchani et al., 2014 (Chouchani et al., , 2016 . These processes lead to an accumulation of malate in the cytosol and of NADH and a reduced CoQ pool in the mitochondria that together enable SDH to reduce fumarate to succinate, which is then exported from the mitochondrion (Figure 1 ). In addition, succinate can also accumulate during ischemia from the breakdown of succinyl CoA (Figure 1 ). This most likely occurs due to 2-oxoglutarate generation from glutaminolysis with the amino group of glutamate then being transferred to pyruvate to generate alanine (Figure 1 ). It is likely that both pathways drive succinate accumulation within ischemic tissue (Chouchani et al., 2014) . In all cases succinate accumulation reflects the highly reduced CoQ pool. Succinate accumulation seems to be a universal marker of ischemia. A further indication that succinate accumulation is a robust reflection of tissue ischemia is that succinate accumulates during anoxia in the carotid body, where it contributes to anoxia sensing (Ferná ndezAgü era et al., 2015).
One further important aspect here is that succinate plays a key role in pathological ischemia reperfusion injury as opposed to being a random process. The rapid oxidation of the succinate within a few minutes of reperfusion reduces the CoQ pool and also hyperpolarizes the mitochondrial inner membrane. Together, these conditions drive RET at complex I, which leads to the dramatic production of ROS (Chouchani et al., 2014 (Chouchani et al., , 2016 . Succinate accumulation is likely to be a key factor in initiating ischemia reperfusion injury in heart attack and stroke. In a more recent example of succinate driving ROS, adipose tissue thermogenesis has been shown to be driven by this process, with succinate acting as a systemic signal for this important metabolic adaptation, further attesting to the role of succinate as a signal (Mills et al., 2018a) .
Succinate in Immune Signaling
In macrophages exposed to the Gram-negative bacterial product lipopolysaccharide (LPS), a dramatic remodeling of metabolism occurs (Tannahill et al., 2013; Mills et al., 2016) . The macrophages switch from relying on oxidative phosphorylation to produce ATP and instead generate ATP by glycolysis while at the same time suppressing oxidative phosphorylation. This metabolic switch is associated with an elevation of succinate levels that largely arises from enhanced glutaminolysis to generate glutamate, which is ultimately converted to succinate as part of the Krebs cycle (Figure 1) .
The pro-inflammatory mode of action of succinate is 2-fold. First, it will be exported to the cytosol and activate Hif1a following PHD inhibition and thus enhance expression of pro-inflammatory genes (Tannahill et al., 2013) . The high level of succinate and the low level of mitochondrial ATP synthesis lead to an elevation in Dp and thus to RET at complex I (Mills et al., 2016) . This requires succinate to be oxidized to fumarate by SDH, but the resulting electrons, instead of proceeding to complex III, are pushed backward into complex I, driving ROS production via RET. This process will also activate HIF1a and is likely to be more important than succinate itself activating HIF1a since the SDH inhibitor dimethyl malonate will block this process. SDH activity will also repress induction of anti-inflammatory genes via an unknown mechanism. Succinate accumulation may well be followed by succinate release from macrophages, which will then act on other cell types via SUCRN1, driving inflammation and also type 2 immunity against pathogens via Tuft cell activation (Lei et al., 2018) (Figure 1 ).
Itaconate as an Anti-inflammatory Metabolite
Just as one component of the Krebs cycle-succinate-can be repurposed to act as a pro-inflammatory signal, another metabolite-itaconate-can also be generated to counteract and resolve the pro-inflammatory pathways activated by succinate. Itaconate has been known to be produced by Aspergillus species since the 1930s (Luan and Medzhitov, 2016) . It is antibacterial, inhibiting the glyoxalate shunt in bacteria (Michelucci et al., 2013) . The production of itaconate within mammalian cells has been demonstrated relatively recently and arises due to the expression of Irg1/Acod1 (immune-regulated gene 1, or aconitate decarboxylase 1) (Luan and Medzhitov, 2016) . IRG1 converts the Krebs cycle metabolite cis-aconitate to itaconate (Michelucci et al., 2013; Strelko et al., 2011) (Figure 1 ). The first demonstration that itaconate might be anti-inflammatory came from a study showing that it can counteract the pro-inflammatory signals of succinate within mitochondria by inhibiting SDH (Lampropoulou et al., 2016; Cordes et al., 2016) . In addition, itaconate activates the Nrf2 pathway (Mills et al., 2016) by reacting with critical thiols on the Nrf2 inhibitor Keap1, enhancing the expression of antioxidant and anti-inflammatory genes (Figure 1) . Succinate therefore drives the initial pro-inflammatory changes within macrophages, and then later, itaconate inhibits SDH and activates Nrf2 (Figure 1 ) to limit inflammation. Itaconate also inhibits the induction of type I interferons, participating in an itaconate/interferon regulatory loop, which may have relevance to viral infections and autoimmune diseases.
Most recently, itaconate has also been shown to induce ATF3 in macrophages, which will repress inflammatory gene expression. (Bambouskova et al., 2018) . Further work is required on the time dependence of the succinate-and itaconate-dependent signals.
Therapeutic Opportunities
In IR injury, the simple SDH inhibitor malonate protected against IR in heart attack and stroke (Chouchani et al., 2014; Valls-Lacalle et al., 2016) . Similarly, this approach protected in an animal model of sepsis (Mills et al., 2016) . The activation of Nrf2 signaling by cell permeable forms of itaconate also suggests new therapeutic approaches to activate this cell-protective pathway. To mimic the anti-inflammatory activity of itaconate within cells requires its delivery to the cytosol, but in most cells, the doubly charged itaconate would be poorly taken up across the plasma membrane (unless there is a transporter). This can be overcome by the use of the simple, cell-permeable itaconate-derivative dimethylitaconate (DMI), which also activates the Nrf2 pathway. DMI is however a far more reactive Michael acceptor than itaconate (ElAzzouny et al., 2017; Mills et al., 2018b) . To overcome these limitations, we developed the itaconate monoester 4-octyl itaconate (4-OI) (Mills et al., 2018b) , whose hydrophobicity enabled far more rapid cell uptake than for itaconate itself, but whose thiol reactivity was the same as that of native itaconate. 4-OI was effective in an animal model of sepsis (Mills et al., 2018b) . However, the hydrophobic octyl group may also affect the activity of this compound; therefore, the future development of itaconate esters with enhanced cell delivery and hydrolysis to itaconate within the cell is a promising area for future development as anti-inflammatory agents. Another option would be to boost IRG1 activity pharmacologically to generate endogenous itaconate. One further point is that itaconate is readily converted to various itaconyl CoA derivatives, which have reactivity distinct from itaconate itself (Shen et al., 2017) , opening up other possibilities for drug development.
Implications and Conclusions
The repurposing of mitochondrial metabolism to use the mitochondrion as a signaling hub utilizing metabolites as indicators of mitochondrial status may be a general principle of metabolic organization. If part of the normal dialog between mitochondria and the cell utilizes the exchange of metabolites, then this indicates new avenues of exploration to both better understand how cells respond to external challenges as well as potentially opening up new therapeutic opportunities. 
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